Moody National Bank Trust Division Trims Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Moody National Bank Trust Division lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% in the second quarter, HoldingsChannel.com reports. The firm owned 13,605 shares of the biopharmaceutical company’s stock after selling 1,104 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $933,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $29,000. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $30,000. Rakuten Securities Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at $33,000. Finally, Gladius Capital Management LP acquired a new position in Gilead Sciences during the 4th quarter worth $34,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock traded down $1.94 on Monday, hitting $74.83. The company’s stock had a trading volume of 7,347,882 shares, compared to its average volume of 7,415,173. The stock has a market cap of $93.23 billion, a price-to-earnings ratio of 208.28, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. The firm has a 50 day moving average of $68.80 and a two-hundred day moving average of $70.66. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Maxim Group decreased their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Finally, Cantor Fitzgerald dropped their price objective on Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Twelve investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $81.81.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.